Skip to main content
SpringerLink
Log in

Low serum levels of total and high-molecular-weight adiponectin predict the development of metabolic syndrome in Japanese-Americans

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Background: Adiponectin is thought to play a significant role in the development of both insulin resistance and metabolic syndrome. Yet, there is very few evidence about the association plasma adiponectin and metabolic syndrome in the prospective study. Adiponectin exists as multimers in serum, and high-molecular-weight (HMW) adiponectin is particularly considered to be the active form of the protein. Aim: We investigated whether serum HMW adiponectin as well as total adiponectin is associated with the development of metabolic syndrome in a longitudinal study. Subjects and methods: We enrolled 224 men and 312 women of Japanese-Americans without metabolic syndrome at baseline who were followed for an average of 3.2 yr. The association of plasma total and HMW adiponectin with a progression to metabolic syndrome was examined. Results: Subjects who developed metabolic syndrome had significantly lower plasma total and HMW adiponectin levels at baseline than those who did not develop metabolic syndrome. In a Cox proportional hazards model, lower total and HMW adiponectin levels were independent risk factors for the development of metabolic syndrome after adjusting for age, body mass index, classification of 75-g glucose tolerance test, and homeostasis model assessment (hazards ratio: total, 0.684, p=0.017, in men; 0.606, p=0.003, in women; HMW, 0.687, p=0.014, in men; 0.704, p=0.029, in women, respectively). Conclusions: Low circulating levels of total and HMW adiponectin may be a possible predictor for the development of metabolic syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221: 286–9.

    Article  PubMed  Google Scholar 

  2. Yang WS, Lee WJ, Funahashi T, et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res 2002, 10: 1104–10.

    Article  PubMed  Google Scholar 

  3. Yamamoto Y, Hirose H, Saito I, et al. Correlation of adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002, 103: 137–42.

    Article  Google Scholar 

  4. Ryo M, Nakamura T, Kihara S, et al. Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004, 68: 975–81.

    Article  PubMed  Google Scholar 

  5. Santaniemi M, Kesäniemi YA, Ukkola O. Low plasma adiponectin concentration is an indicator of the metabolic syndrome. Eur J Endocrinol 2006, 155: 745–50.

    Article  PubMed  Google Scholar 

  6. Matsushita K, Yatsuya H, Tamakoshi K, et al. Comparison of circulating adiponectin and proimflammatory markers regarding their association with metabolic syndrome in Japanese men. Arterioscler Thromb Vasc Biol 2006, 26: 871–6.

    Article  PubMed  Google Scholar 

  7. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 2003, 278: 40352–63.

    Article  PubMed  Google Scholar 

  8. Pajvani UB, Du X, Combs TP, et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003, 278: 9073–85.

    Article  PubMed  Google Scholar 

  9. Aso Y, Yamamoto R, Wakabayashi S, et al. Comparison of serum high-molecular weight (HMW) adiponectin with total adiponectin concentrations in type 2 diabetic patients with coronary artery disease using a novel enzyme-linked immunosorbent assay to detect HMW adiponectin. Diabetes 2006, 55: 1954–60.

    Article  PubMed  Google Scholar 

  10. Hara K, Horikoshi M, Yamauchi T, et al. Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006, 29: 1357–62.

    Article  PubMed  Google Scholar 

  11. Nakashima R, Kamei N, Yamane K, Nakanishi S, Nakashima A, Kohno N. Decreased total and high molecular weight adiponectin are independent risk factors for the development of type 2 diabetes in Japanese-Americans. J Clin Endocrinol Metab 2006, 91: 3873–7.

    Article  PubMed  Google Scholar 

  12. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997, 20: 1183–97.

    Google Scholar 

  13. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association, National Heart, Lung, and Blood Institute. Diagnosis and manegement of the metabolic syndrome. Circulation 2005, 112: 2735–52.

    Article  PubMed  Google Scholar 

  14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.

    Article  PubMed  Google Scholar 

  15. Kern PA, Di Gregorio GB, Lu T, Rassouli N, Ranganathan G. Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes 2003, 52: 1779–85.

    Article  PubMed  Google Scholar 

  16. Lindsay RS, Funahashi T, Hanson RL, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002, 360: 57–8.

    Article  PubMed  Google Scholar 

  17. Tabara Y, Osawa H, Kawamoto R, et al. Reduced high-molecular-weight adiponectin and elevated high-sensitivity C-reactive protein are synergic risk factors for metabolic syndrome in a large-scale middle-aged to elderly population: the Shimanami Health Promoting Program Study. J Clin Endocrinol Metab 2007, 93: 715–22.

    Article  PubMed  Google Scholar 

  18. Seino Y, Hirose H, Saito I, Itoh H. High-molecular-weight adiponectin isa predictor of progression to metabolic syndrome: a population-based 6-year follow-up study in Japanese men. Metabolism 2009, 58: 355–60.

    Article  PubMed  Google Scholar 

  19. Tankó LB, Bruun JM, Alexandersen P, et al. Novel associations between bioavailable estradiol and adipokines in elderly women with different phenotypes of obesity: implications for atherogenesis. Circulation 2004, 110: 2246–52.

    Article  PubMed  Google Scholar 

  20. Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005, 280: 18073–80.

    Article  PubMed  Google Scholar 

  21. Kubota N, Terauchi Y, Yamauchi T, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002, 277: 25863–6.

    Article  PubMed  Google Scholar 

  22. Maeda N, Shimomura I, Kishida K, et al. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8: 731–7.

    Article  PubMed  Google Scholar 

  23. Egusa G, Watanabe H, Ohshita K, et al. Influence of the extent of westernization of lifestyle on the progression of preclinical atherosclerosis in Japanese subjects. J Atheroscler Thromb 2002, 9: 299–304.

    Article  PubMed  Google Scholar 

  24. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the “metabolic syndrome” and incidence of type 2 diabetes. Diabetes 2002, 51: 3120–7.

    Article  PubMed  Google Scholar 

  25. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009, 302: 179–88.

    Article  PubMed  Google Scholar 

  26. Hara K, Boutin P, Mori Y, et al. Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in Japanese population. Diabetes 2002, 51: 536–40.

    Article  PubMed  Google Scholar 

  27. Dzau VJ, Bernstein K, Celermajer D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002, 16: 149–60.

    Article  PubMed  Google Scholar 

  28. Sakamoto K, Sakamoto T, Ogawa H, et al. The effect of 6 months of treatment with pravastatin on serum adiponectin concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther 2006, 28: 1012–21.

    Article  PubMed  Google Scholar 

  29. Sugiyama S, Fukushima H, Kugiyama K, et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194: 43–51.

    Article  Google Scholar 

  30. Oki K, Koide J, Nakanishi S, Nakashima R, Yamane K. Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglycedemia. Endocr J 2007, 54: 431–5.

    Article  PubMed  Google Scholar 

  31. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett 2001, 507: 142–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3 Kasumi Minami-Ku, Hiroshima City, 734-8551, Japan

    R. Nakashima, K. Yamane MD, PhD, N. Kamei, S. Nakanishi & N. Kohno

Authors
  1. R. Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Yamane MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. Kamei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Nakanishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. N. Kohno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Yamane MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakashima, R., Yamane, K., Kamei, N. et al. Low serum levels of total and high-molecular-weight adiponectin predict the development of metabolic syndrome in Japanese-Americans. J Endocrinol Invest 34, 615–619 (2011). https://doi.org/10.3275/7409

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3275/7409

Key-words

Search

Navigation